Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS

BACKGROUND: In PARADIGMS, a double-blind phase III trial in 215 paediatric patients with multiple sclerosis (MS) (10 to <18 years), fingolimod administered for up to 2 years significantly reduced the annualised relapse rate (ARR) and rate of new/newly enlarged T2 (n/neT2) lesions compared with in...

Descripción completa

Detalles Bibliográficos
Autores principales: Deiva, Kumaran, Huppke, Peter, Banwell, Brenda, Chitnis, Tanuja, Gärtner, Jutta, Krupp, Lauren, Waubant, Emmanuelle, Stites, Tracy, Pearce, Gregory Lewis, Merschhemke, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952840/
https://www.ncbi.nlm.nih.gov/pubmed/31467033
http://dx.doi.org/10.1136/jnnp-2019-321124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952840/
https://www.ncbi.nlm.nih.gov/pubmed/31467033
http://dx.doi.org/10.1136/jnnp-2019-321124

Ejemplares similares